FLEX Shows Erbitux Strength In NSCLC, CRYSTAL Offers KRAS Biomarker

With positive results of the Phase III FLEX study in hand - showing an overall survival benefit for Erbitux in first-line non-small cell lung cancer - Bristol-Myers Squibb and partner ImClone are discussing with FDA their plans to use the data as the basis of a supplemental BLA filing, Bristol said in an interview